Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.53 |
| ▸ | MAP3K8 | P41279 | 4/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | SLC2A2 | P11168 | 2/20 | 0.33 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | PRKCG | P05129 | 1/20 | 0.33 |
| ▸ | PRKCB | P05771 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | PRKCH | P24723 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.33 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.33 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.33 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12835842 | 0.86 | GSK3B (0.72) | GSK3BMAP3K8MAPK13PRKD3PRKCG | |
| Hydrochloric Acid SCHEMBL1514127 | 0.85 | GSK3B (0.71) | GSK3BMAP3K8MAPK13PRKD3PRKCG | |
| SCHEMBL8143251 | 0.84 | GSK3B (0.45) | GSK3BSLC2A2ALDH1A1CYP2A13GSK3A | |
| Trifluoroacetic Acid SCHEMBL1514015 | 0.82 | GSK3B (0.45) | GSK3BSLC2A2ALDH1A1GSK3A | |
| SCHEMBL8144904 | 0.81 | GSK3B (0.55) | GSK3BARSLC2A2MOKALDH1A1 | |
| SCHEMBL15080867 | 0.81 | GSK3B (0.52) | GSK3BALDH1A1GSK3A | |
| SCHEMBL8142279 | 0.80 | GSK3B (0.52) | GSK3BGSK3A | |
| SCHEMBL8135071 | 0.78 | GSK3B (0.73) | GSK3BGSK3A | |
| SCHEMBL12680872 | 0.78 | MAP3K8 (0.35) | GSK3BMAP3K8ARSLC2A2MOK | |
| SCHEMBL12835855 | 0.77 | GSK3B (0.74) | GSK3BMAP3K8SRCGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434731-B2 | Imidazo-, pyrazolopyrazines and imidazotriazines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-20130261115-A1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-03 | — | — | US | disclosed |
| US-8476267-B2 | Imidazo-, pyrazolopyrazines and imidazotriazines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| US-20110053929-A1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053929-A1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE | THPO, TPMT, IKZF3 | GSK3B 4433/4885MAP3K8 563/4885AR 4025/4885 |
| US-20130261115-A1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE | THPO, TPMT, IKZF3 | GSK3B 4433/4885MAP3K8 563/4885AR 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.